Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus with Low Dose Corticosteroid in MCNS
NCT01084980Phase 3Completed
- Sponsor
- Seoul National University Hospital
- Start
- Jun 2010
- Primary completion
- Jul 2011
- Modality
- RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tacrolimus in minimal change disease (MCD), sponsored by Seoul National University Hospital. Primary endpoint: Remission of proteinuria at 12 weeks. Started Jun 2010; status: completed.
02
Drugs
tacrolimus
03
Conditions
minimal change disease (MCD)
Beyond the preview
Go deeper on NCT01084980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01084980.